Cargando…

Human HLA-F adjacent transcript 10 promotes the formation of cancer initiating cells and cisplatin resistance in bladder cancer

Epithelial to mesenchymal transition (EMT) serves important roles in tumor invasion, metastasis, formation of cancer initiating cells (CICs) and drug resistance. HLA-F adjacent transcript 10 (FAT10) has been proposed as an oncogene in bladder cancer. However, the functional contribution of FAT10 to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Chen, Wang, Zhenfan, Feng, Ninghan, Dong, Jian, Deng, Xiaoyan, Yue, Yin, Guo, Yuehong, Hou, Jianquan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2018
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6059684/ https://www.ncbi.nlm.nih.gov/pubmed/29749526 http://dx.doi.org/10.3892/mmr.2018.9005

Ejemplares similares

TACC3 transcriptionally upregulates E2F1 to promote cell growth and confer sensitivity to cisplatin in bladder cancer
por: Lin, Zhi-Rui, et al.
Publicado: (2018)

Mechanism Study on Radiosensitization Effect of Curcumin in Bladder Cancer Cells Regulated by Filamin A
por: Wang, Zhenfan, et al.
Publicado: (2022)

The prognostic value of histological subtype in patients with metastatic bladder cancer
por: Chen, Cheng, et al.
Publicado: (2017)

The effect of cisplatin in 5637 bladder cancer cell line
por: Pinto-Leite, Rosário, et al.
Publicado: (2010)

Reprogrammed lipid metabolism in bladder cancer with cisplatin resistance
por: Lee, Min Young, et al.
Publicado: (2018)

Targeting HNRNPU to overcome cisplatin resistance in bladder cancer
por: Shi, Zhen-duo, et al.
Publicado: (2022)

Preoperative Anemia as a Simple Prognostic Factor in Patients with Urinary Bladder Cancer
por: Chen, Cheng, et al.
Publicado: (2017)

Phase II Study of Induction Chemotherapy with Docetaxel, Capecitabine, and Cisplatin Plus Bevacizumab for Initially Unresectable Gastric Cancer with Invasion of Adjacent Organs or Paraaortic Lymph Node Metastasis
por: Kim, Jwa Hoon, et al.
Publicado: (2018)

FOXO1 inactivation induces cisplatin resistance in bladder cancer
por: Ide, Hiroki, et al.
Publicado: (2020)

Piperlongumine increases the sensitivity of bladder cancer to cisplatin by mitochondrial ROS
por: Pan, Xiaobo, et al.
Publicado: (2022)

Maspin enhances cisplatin chemosensitivity in bladder cancer T24 and 5637 cells and correlates with prognosis of muscle-invasive bladder cancer patients receiving cisplatin based neoadjuvant chemotherapy
por: Chen, Jinbo, et al.
Publicado: (2016)

HLA-G and HLA-F protein isoform expression in breast cancer patients receiving neoadjuvant treatment
por: Wuerfel, Franziska M., et al.
Publicado: (2020)

Cisplatin, Gemcitabine, and Lapatinib as Neoadjuvant Therapy for Muscle-Invasive Bladder Cancer
por: Narayan, Vivek, et al.
Publicado: (2016)

An Epigenomic Approach to Improving Response to Neoadjuvant Cisplatin Chemotherapy in Bladder Cancer
por: Xylinas, Evanguelos, et al.
Publicado: (2016)

Androgen receptor activity modulates responses to cisplatin treatment in bladder cancer
por: Kashiwagi, Eiji, et al.
Publicado: (2016)

Natural products as a means of overcoming cisplatin chemoresistance in bladder cancer
por: Rajendran, Ganeshkumar, et al.
Publicado: (2021)

FOXC1 Binds Enhancers and Promotes Cisplatin Resistance in Bladder Cancer
por: Lu, Yi-Tsung, et al.
Publicado: (2022)

Methionine orchestrates the metabolism vulnerability in cisplatin resistant bladder cancer microenvironment
por: Yang, Chen, et al.
Publicado: (2023)

Suppression of progranulin expression inhibits bladder cancer growth and sensitizes cancer cells to cisplatin
por: Buraschi, Simone, et al.
Publicado: (2016)

Identification of a Novel Ferroptosis-Related Gene Prognostic Signature in Bladder Cancer
por: Sun, Jiale, et al.
Publicado: (2021)

Cytoskeleton regulator RNA expression on cancer-associated fibroblasts is associated with prognosis and immunotherapy response in bladder cancer
por: Wu, Yucai, et al.
Publicado: (2023)

Cordycepin Resensitizes T24R2 Cisplatin-Resistant Human Bladder Cancer Cells to Cisplatin by Inactivating Ets-1 Dependent MDR1 Transcription
por: Oh, Sang-Seok, et al.
Publicado: (2020)

STC1 is a Novel Biomarker Associated with Immune Characteristics and Prognosis of Bladder Cancer
por: Sun, Jiale, et al.
Publicado: (2021)

OIP5 Promotes Growth, Metastasis and Chemoresistance to Cisplatin in Bladder Cancer Cells
por: Wang, Dailian, et al.
Publicado: (2018)

Pterostilbene Sensitizes Cisplatin-Resistant Human Bladder Cancer Cells with Oncogenic HRAS
por: Chen, Yi-Ting, et al.
Publicado: (2020)

S-Palmitoylation as a Functional Regulator of Proteins Associated with Cisplatin Resistance in Bladder Cancer
por: Shahid, Muhammad, et al.
Publicado: (2020)

CD40 is Positively Correlated with the Expression of Nucleophosmin in Cisplatin-Resistant Bladder Cancer
por: Luo, Chenshuo, et al.
Publicado: (2020)

Interleukin-35 as a predictor of prostate cancer in patients undergoing initial prostate biopsy
por: Zhou, Chenchao, et al.
Publicado: (2017)

Upregulated expression of BCL2, MCM7, and CCNE1 indicate cisplatin-resistance in the set of two human bladder cancer cell lines: T24 cisplatin sensitive and T24R2 cisplatin resistant bladder cancer cell lines
por: Kim, Sung Han, et al.
Publicado: (2016)

Inflammatory microenvironment in the initiation and progression of bladder cancer
por: Sui, Xinbing, et al.
Publicado: (2017)

fMRI Evidence of Acupoints Specificity in Two Adjacent Acupoints
por: Liu, Hua, et al.
Publicado: (2013)

Fusion Transcripts of Adjacent Genes: New Insights into the World of Human Complex Transcripts in Cancer
por: Barresi, Vincenza, et al.
Publicado: (2019)

Anti-cancer properties of cannflavin A and potential synergistic effects with gemcitabine, cisplatin, and cannabinoids in bladder cancer
por: Tomko, Andrea M., et al.
Publicado: (2022)

Vinorelbine in bladder-preserving multimodality treatment for muscle-invasive bladder cancer—a valid option for cisplatin-unfit patients?
por: Arnold, C. R., et al.
Publicado: (2021)

Transcriptional overlap links DNA hypomethylation with DNA hypermethylation at adjacent promoters in cancer
por: Fain, Jean S., et al.
Publicado: (2021)

Epigenetic silencing of miR-200b is associated with cisplatin resistance in bladder cancer
por: Shindo, Tetsuya, et al.
Publicado: (2018)

PKM2 Inhibitor Shikonin Overcomes the Cisplatin Resistance in Bladder Cancer by Inducing Necroptosis
por: Wang, Yonggang, et al.
Publicado: (2018)

Hypoxia-elevated circELP3 contributes to bladder cancer progression and cisplatin resistance
por: Su, Yinjie, et al.
Publicado: (2019)

Capillary leak syndrome induced by neoadjuvant cisplatin and gemcitabine in a patient with bladder cancer
por: Massafra, Marco, et al.
Publicado: (2020)

Successful treatment of metastatic bladder cancer by gemcitabine‐cisplatin re‐challenge after pembrolizumab
por: Arai, Takayuki, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_9124fuc2qalilbk3etn0g5sroc